Efficacy and acceptability of interventions for attenuated positive psychotic symptoms in individuals at clinical high risk of psychosis: A network meta-analysis

Frontiers in Psychiatry

Volumn 9, Issue JUN, 2018, Pages

  Davies, Cathy ^a   Radua, Joaquim ^a,b,c   Cipriani, Andrea ^d,e   Stahl, Daniel ^a   Provenzani, Umberto ^a,f   McGuire, Philip ^a,g,h   Fusar Poli, Paolo ^a,f,g,h  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^c KAROLINSKA INSTITUTE   (Sweden)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e OXFORD HEALTH NHS FOUNDATION TRUST   (United Kingdom)

^f UNIVERSITY OF PAVIA   (Italy)

^g King s College London   (United Kingdom)

^h SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Interventions; Network meta analysis; Psychosis; Risk; Symptoms; Treatments

Indexed keywords

ARIPIPRAZOLE; OLANZAPINE; PLACEBO; RISPERIDONE; ZIPRASIDONE;

ADULT; CLINICAL EFFECTIVENESS; COGNITIVE BEHAVIORAL THERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; EVIDENCE BASED PRACTICE; FEMALE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SENSITIVITY ANALYSIS; TREATMENT DURATION;

EID: 85048640423     PISSN: None     EISSN: 16640640     Source Type: Journal    
DOI: 10.3389/fpsyt.2018.00187     Document Type: Review

References (94)

1. Fusar-Poli P. The clinical high-risk state for psychosis (CHR-P), Version II. Schizophr Bull. (2017) 43:44-7. doi: 10.1093/schbul/sbw158
2. Fusar-Poli P, McGorry PD, Kane JM. Improving outcomes of first-episode psychosis: an overview. World Psychiatry (2017) 16:251-65. doi: 10.1002/wps.20446
3. Millan MJ, rieux A, Bartzokis G, Cadenhead K, Dazzan P, Fusar-Poli P, et al. Altering the course of schizophrenia: progress and perspectives. Nat Rev Drug Discov. (2016) 5:485-51. doi: 10.1038/nrd.2016.28
4. Oliver D, Davies C, Crossland G, Lim S, Gifford G, McGuire P, et al. Can we reduce the duration of untreated psychosis? A meta-analysis of controlled interventional studies. Schizophr Bull. (2018). doi: 10.1093/schbul/sbx166. [Epub ahead of print]
5. Fusar-Poli P, Tantardini M, De Simone S, Ramella-Cravaro V, Oliver D, Kingdon J, et al. Deconstructing vulnerability for psychosis: Meta-analysis of environmental risk factors for psychosis in subjects at ultra high-risk. Eur Psychiatry (2017) 40:65-75. doi: 10.1016/j.eurpsy.2016.09.003
6. Yung A, Yuen H, McGorry P, Phillips L, Kelly D, Dell'Olio M, et al. Mapping the onset of psychosis: the Comprehensive Assessment of At-Risk Mental States. Aust N Z J Psychiatry (2005) 39:964-71. doi: 10.1080/j.1440-1614.2005.01714.x
7. Fusar-Poli P, Rocchetti M, Sardella A, Avila A, Brandizzi M, Caverzasi E, et al. Disorder, not just a state of risk: meta-analysis of functioning and quality of life in subjects at high clinical risk for psychosis. Br J Psychiatry (2015) 207:198-206. doi: 10.1192/bjp.bp.114.157115
8. Falkenberg I, Valmaggia L, Byrnes M, Frascarelli M, Jones C, Rocchetti M, et al. Why are help-seeking subjects at ultra-high risk for psychosis help-seeking? Psychiatry Res. (2015) 228:808-15. doi: 10.1016/j.psychres.2015.05.018
9. Fusar-Poli P, Cappucciati M, Borgwardt S, Woods SW, Addington J, Nelson B, et al. Heterogeneity of psychosis risk within individuals at clinical high risk. JAMA Psychiatry (2016) 73:113. doi: 10.1001/jamapsychiatry.2015.2324
10. Webb JR, Addington J, Perkins DO, Bearden CE, Cadenhead KS, Cannon TD, et al. Specificity of incident diagnostic outcomes in patients at clinical high risk for psychosis. Schizophr Bull. (2015) 41:1066-75. doi: 10.1093/schbul/sbv091
11. Fusar-Poli P, Rutigliano G, Stahl D, Davies C, De Micheli A, Ramella-Cravaro V, et al. Long-term validity of the at risk mental state (ARMS) for predicting psychotic and non-psychotic mental disorders. Eur Psychiatry 2017:49-54. doi: 10.1016/j.eurpsy.2016.11.010
12. Fusar-Poli P. The hype cycle of the clinical high risk state for psychosis: the need of a refined approach. Schizophr Bull. (2018) 44:250-53. doi: 10.1093/schbul/sbx181
13. Fusar-Poli P, Rutigliano G, Stahl D, Davies C, Bonoldi I, Reilly T, et al. Development and validation of a clinically based risk calculator for the transdiagnostic prediction of psychosis. JAMA Psychiatry (2017) 74:493-500. doi: 10.1001/jamapsychiatry.2017.0284
14. Fusar-Poli P. Extending the benefits of indicated prevention to improve outcomes of first-episode psychosis. JAMA Psychiatry (2017) 74:667-8. doi: 10.1001/jamapsychiatry.2017.1009
15. Oliver D, Kotlicka-Antczak M, Minichino A, Spada G, McGuire P, Fusar-Poli P. Meta-analytical prognostic accuracy of the Comprehensive Assessment of At Risk Mental States (CAARMS): the need for a refined prediction. Eur Psychiatry (2018) 49:62-8. doi: 10.1016/j.eurpsy.2017.10.001
16. Fusar-Poli P, Palombini E, Davies C, Oliver D, Bonoldi I, Ramella-Cravaro V, et al. Why transition risk to psychosis is not declining at the OASIS ultra high risk service: the hidden role of stable pretest risk enrichment. Schizophr Res. (2017) 92:385-90. doi: 10.1016/j.schres.2017.06.015
17. Fusar-Poli P, Rutigliano G, Stahl D, Schmidt A, Ramella-Cravaro V, Shetty H, et al. Deconstructing pretest risk enrichment to optimize prediction of psychosis in individuals at clinical high risk. JAMA Psychiatry (2016) 73:1260-7. doi: 10.1001/jamapsychiatry.2016.2707
18. Fusar-Poli P, Schultze-Lutter F, Cappucciati M, Rutigliano G, Bonoldi I, Stahl D, et al. The dark side of the moon: meta-analytical impact of recruitment strategies on risk enrichment in the clinical high risk state for psychosis. Schizophr Bull. (2016) 42:732-43. doi: 10.1093/schbul/sbv162
19. Fusar-Poli P. Why ultra high risk criteria for psychosis prediction do not work well outside clinical samples and what to do about it. World Psychiatry (2017) 16:212-3. doi: 10.1002/wps.20405
20. Fusar-Poli P, Schultze-Lutter F. Predicting the onset of psychosis in patients at clinical high risk: practical guide to probabilistic prognostic reasoning. Evid Based Ment Health (2016) 19:10-5. doi: 10.1136/eb-2015-102295
21. Leucht S, Chaimani A, Cipriani AS, Davis JM, Furukawa TA, Salanti G. Network meta-analyses should be the highest level of evidence in treatment guidelines. Eur Arch Psychiatry Clin Neurosci. (2016) 266:477-80. doi: 10.1007/s00406-016-0715-4
22. Davies C, Cipriani A, Ioannidis JP, Radua J, Stahl D, Provenzani U, et al. Lack of evidence to favor specific preventive interventions in psychosis: a network meta-analysis. World Psychiatry (2018) 17:196-209. doi: 10.1002/wps.20526
23. Fusar-Poli P. Negative psychosis prevention trials. JAMA Psychiatry (2017) 74:651. doi: 10.1001/jamapsychiatry.2017.0185
24. Bechdolf A, Müller H, Stützer H, Lambert M, Karow A, Zink M, et al. 108. PREVENT: a randomized controlled trial for the prevention of first-episode psychosis comparing cognitive-behavior therapy (CBT), clinical management, and aripiprazole combined and clinical management and placebo combined. Schizophr Bull. (2016) 43:S56. doi: 10.1093/schbul/sbx021.146
25. Cadenhead K, Addington J, Cannon T, Cornblatt B, Mathalon D, McGlashan T, et al. 23. Omega-3 fatty acid versus placebo in a clinical high-risk sample from the north american prodrome longitudinal studies (NAPLS) consortium. Schizophr Bull. (2017) 43:S16. doi: 10.1093/schbul/sbx021.042
26. Kantrowitz JT, Woods SW, Petkova E, Cornblatt B, Corcoran CM, Chen H, et al. D-serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double-blind, placebo-controlled, randomised parallel group mechanistic proof-of-concept trial. Lancet Psychiatry (2015) 2:403-12. doi: 10.1016/S2215-0366(15)00098-X
27. McGorry PD, Nelson B, Markulev C, Yuen HP, Schäfer MR, Mossaheb N, et al. Effect of ω-3 polyunsaturated fatty acids in young people at ultrahigh risk for psychotic disorders. JAMA Psychiatry (2017) 74:19. doi: 10.1001/jamapsychiatry.2016.2902
28. Miklowitz DJ, O'Brien MP, Schlosser DA, Addington J, Candan KA, Marshall C, et al. Family-focused treatment for adolescents and young adults at high risk for psychosis: results of a randomized trial. J Am Acad Child Adolesc Psychiatry (2014) 53:848-58. doi: 10.1016/j.jaac.2014.04.020
29. Stain HJ, Bucci S, Baker AL, Carr V, Emsley R, Halpin S, et al. A randomised controlled trial of cognitive behaviour therapy versus non-directive reflective listening for young people at ultra high risk of developing psychosis: the detection and evaluation of psychological therapy (DEPTh) trial. Schizophr Res. (2016) 176:212-9. doi: 10.1016/j.schres.2016.08.008
30. Woods S, Saksa J, Compton M, Daley M, Rajarethinam R, Graham K, et al. 112. Effects of ziprasidone versus placebo in patients at clinical high risk for psychosis. Schizophr Bull. (2017) 43:S58. doi: 10.1093/schbul/sbx021.150
31. Woods SW. Ziprasidone in the Psychosis Prodrome (ZIP) ClinicalTrials.gov Identifier: NCT00635700 [Last updated: September 6, 2016]. (2016)
32. Rutigliano G, Valmaggia L, Landi P, Frascarelli M, Cappucciati M, Sear V, et al. Persistence or recurrence of non-psychotic comorbid mental disorders associated with 6-year poor functional outcomes in patients at ultra high risk for psychosis. J Affect Disord. (2016) 203:101-10. doi: 10.1016/j.jad.2016.05.053
33. Fusar-Poli P, Raballo A, Parnas J. What is an attenuated psychotic symptom? on the importance of the context. Schizophr Bull. (2017) 43:687-92. doi: 10.1093/schbul/sbw182
34. Fusar-Poli P, Cappucciati M, Rutigliano G, Lee TY, Beverly Q, Bonoldi I, et al. Towards a standard psychometric diagnostic interview for subjects at ultra high risk of psychosis: CAARMS versus SIPS. Psychiatry J. (2016) 2016:7146341. doi: 10.1155/2016/7146341
35. Fusar-Poli P, Van Os J. Lost in transition: setting the psychosis threshold in prodromal research. Acta Psychiatr Scand. (2013) 127:248-52. doi: 10.1111/acps.12028
36. NICE. Psychosis and Schizophrenia in Adults: Prevention and Management. (2014). Available online at: https://www.nice.org.uk/guidance/cg178/chapter/1-Recommendations#preventing-psychosis-2
37. Addington J, Epstein I, Liu L, French P, Boydell KM, Zipursky RB. A randomized controlled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis. Schizophr Res. (2011) 125:54-61. doi: 10.1016/j.schres.2010.10.015
38. McGorry PD, Yung AR, Phillips LJ, Yuen HP, Francey S, Cosgrave EM, et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry (2002) 59:921. doi: 10.1001/archpsyc.59.10.921
39. Yung AR, McGorry PD, Francey SM, Nelson B, Baker K, Phillips LJ, et al. PACE: a specialised service for young people at risk of psychotic disorders. Med J Aust. (2007) 187:S43-6
40. Amminger GP, Schäfer MR, Papageorgiou K, Klier MC, Cotton MS, Harrigan MS, et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders. Arch Gen Psychiatry (2010) 67:146-54. doi: 10.1001/archgenpsychiatry.2009.192
41. French P, Morrison A. Early Detection and Cognitive Therapy for People at High Risk of Developing Psychosis. Chichester: Wiley (2004) p.117-20
42. Beck AT. Cognitive Therapy and the Emotional Disorders. Madison: International University Press (1976)
43. Morrison AP, French P, Walford L, Lewis SW, Kilcommons A, Green J, et al. Cognitive therapy for the prevention of psychosis in people at ultra-high risk: randomised controlled trial. Br J Psychiatry (2004) 185:291-7. doi: 10.1192/bjp.185.4.291
44. van der Gaag M, Nieman DH, Rietdijk J, Dragt S, Ising HK, Klaassen RMC, et al. Cognitive behavioral therapy for subjects at ultrahigh risk for developing psychosis: a randomized controlled clinical trial. Schizophr Bull. (2012) 38:1180-8. doi: 10.1093/schbul/sbs105
45. Rietdijk J, Dragt S, Klaassen R, Ising H, Nieman D, Wunderink L, et al. A single blind randomized controlled trial of cognitive behavioural therapy in a help-seeking population with an At Risk Mental State for psychosis: the Dutch Early Detection and Intervention Evaluation (EDIE-NL) trial. Trials (2010) 11:30. doi: 10.1186/1745-6215-11-30
46. Bechdolf A, Wagner M, Ruhrmann S, Harrigan S, Putzfeld V, Pukrop R, et al. Preventing progression to first-episode psychosis in early initial prodromal states. Br J Psychiatry (2012) 200:22-9. doi: 10.1192/bjp.bp.109.066357
47. Bechdolf A, Puetzfeld V, Gross S, Guettgemanns J. Cognitive behaviour therapy for people at-risk of psychosis. A Treatment Manual. Bern: Huber. (2010)
48. Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. (2015) 162:777. doi: 10.7326/M14-2385
49. Fusar-Poli P, Borgwardt S, Bechdolf A, Addington J, Riecher-Rossler A, Schultze-Lutter F, et al. The psychosis high-risk state a comprehensive state-of-the-art review. JAMA Psychiatry (2013) 70:107-20. doi: 10.1001/jamapsychiatry.2013.269
50. McGlashan T, Walsh B, Woods S. The Psychosis-Risk Syndrome: Handbook for Diagnosis and Follow-Up. Oxford: Oxford University Press (2010)
51. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. (1987) 13:261-76. doi: 10.1093/schbul/13.2.261
52. Overall J, Gorham D. The brief psychiatric rating scale (BPRS): recent developments in ascertainment and scaling. Psychopharmacol Bull. (1988) 24:97-9
53. Haefner H, Bechdolf A, Klosterkotter J, Maurer K. Early Detection and Intervention in Psychosis. A Practise Handbook. Stuttgart: Schattauer (2011)
54. Cipriani A, Zhou X, Del Giovane C, Hetrick SE, Qin B, Whittington C, et al. Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis. Lancet (2016) 388:881-90. doi: 10.1016/S0140-6736(16)30385-3
55. Kempton MJ, Bonoldi I, Valmaggia L, McGuire P, Fusar-Poli P. Speed of psychosis progression in people at ultra-high clinical risk. JAMA Psychiatry (2015) 72:622. doi: 10.1001/jamapsychiatry.2015.0094
56. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet (2009) 373:746-58. doi: 10.1016/S0140-6736(09)60046-5
57. Cipriani A, Barbui C, Salanti G, Rendell J, Brown R, Stockton S, et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet (2011) 378:1306-15. doi: 10.1016/S0140-6736(11)60873-8
58. Miura T, Noma H, Furukawa TA, Mitsuyasu H, Tanaka S, Stockton S, et al. Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network meta-analysis. Lancet Psychiatry (2014) 1:351-9. doi: 10.1016/S2215-0366(14)70314-1. [Epub ahead of print]
59. Higgins JPT, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ (2011) 343:d5928. doi: 10.1136/bmj.d5928
60. Furukawa TA, Salanti G, Atkinson LZ, Leucht S, Ruhe HG, Turner EH, et al. Comparative efficacy and acceptability of first-generation and second-generation antidepressants in the acute treatment of major depression: protocol for a network meta-analysis. BMJ Open (2016) 6:e010919. doi: 10.1136/bmjopen-2015-010919
61. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Introduction to Meta-Analysis. Chichester: John Wiley & Sons, Ltd. (2009)
62. Higgins JPT, Green S. (eds). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration (2011). Available online at: http://handbook.cochrane.org
63. Chaimani A, Higgins JPT, Mavridis D, Spyridonos P, Salanti G. Graphical tools for network meta-analysis in STATA. PLoS ONE (2013) 8:e76654. doi: 10.1371/journal.pone.0076654
64. Chaimani A, Salanti G. Visualizing assumptions and results in network meta-analysis: the network graphs package. Stata J. (2015) 15:905-50
65. White IR. Multivariate random-effects meta-regression: updates to mvmeta. Stata J. (2011) 11:255-70
66. Mavridis D, Giannatsi M, Cipriani A, Salanti G. A primer on network meta-analysis with emphasis on mental health. Evid Based Mental Health (2015) 18:40-6. doi: 10.1136/eb-2015-102088
67. Salanti G, Ades AE, Ioannidis JPA. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. (2011) 64:163-71. doi: 10.1016/j.jclinepi.2010.03.016
68. Mbuagbaw L, Rochwerg B, Jaeschke R, Heels-Andsell D, Alhazzani W, Thabane L, et al. Approaches to interpreting and choosing the best treatments in network meta-analyses. Syst Rev. (2017) 6:79. doi: 10.1186/s13643-017-0473-z
69. Higgins JPT, Jackson D, Barrett JK, Lu G, Ades AE, White IR. Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Res Synth Methods (2012) 3:98-110. doi: 10.1002/jrsm.1044
70. Chaimani A, Salanti G, Leucht S, Geddes JR, Cipriani A. Common pitfalls and mistakes in the set-up, analysis and interpretation of results in network meta-analysis: what clinicians should look for in a published article. Evid Based Ment Health. (2017) 20:88-94. doi: 10.1136/eb-2017-102753
71. Chaimani A, Salanti G. Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions. Res Synth Methods (2012) 3:161-76. doi: 10.1002/jrsm.57
72. Fusar-Poli P, Papanastasiou E, Stahl D, Rocchetti M, Carpenter W, Shergill S, et al. Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebo-controlled trials. Schizophr Bull. (2015) 41:892-9. doi: 10.1093/schbul/sbu170
73. McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW, et al. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry (2006) 163:790-9. doi: 10.1176/ajp.2006.163.5.790
74. Morrison AP, French P, Stewart SL, Birchwood M, Fowler D, Gumley AI, et al. Early detection and intervention evaluation for people at risk of psychosis: multisite randomised controlled trial. BMJ (2012) 344:e2233. doi: 10.1136/bmj.e2233
75. Wessels H, Wagner M, Frommann I, Berning J, Putzfeld V, Janssen B, et al. Neuropsychological functioning as a predictor of treatment response to psychoeducational, cognitive behavioral therapy in people at clinical high risk of first episode psychosis. Psychiatr Prax. (2015) 42:313-9. doi: 10.1055/s-0035-1552713
76. Yung AR, Phillips LJ, Nelson B, Francey SM, PanYuen H, Simmons MB, et al. Randomized controlled trial of interventions for young people at ultra high risk for psychosis. J Clin Psychiatry (2011) 72:430-40. doi: 10.4088/JCP.08m04979ora
77. McGorry PD, Nelson B, Phillips LJ, Yuen HP, Francey SM, Thampi A, et al. Randomized controlled trial of interventions for young people at ultra-high risk of psychosis: twelve-month outcome. J Clin Psychiatry (2013) 74:349-56. doi: 10.4088/JCP.12m07785
78. Devoe J, Peterson A, Addington J. Negative symptom interventions in youth at risk of psychosis: a systematic review and network meta-analysis. Schizophr Bull. (2018). doi: 10.1093/schbul/sbx139
79. Devoe J, Peterson A, Addington J. Erratum to: Negative symptom interventions in youth at risk of psychosis: a systematic review and network meta-analysis. Schizophr Bull. (2018) 44:463. doi: 10.1093/schbul/sbx193
80. Schmidt SJ, Schultze-Lutter F, Schimmelmann BG, Maric NP, Salokangas RKR, Riecher-Rössler a, et al. EPA guidance on the early intervention in clinical high risk states of psychoses. Eur Psychiatry (2015) 30:388-404. doi: 10.1016/j.eurpsy.2015.01.013
81. Hutton P, Taylor PJ. Cognitive behavioural therapy for psychosis prevention: a systematic review and meta-analysis. Psychol Med. (2014) 44:449-68. doi: 10.1017/S0033291713000354
82. van der Gaag M, Smit F, Bechdolf A, French P, Linszen DH, Yung AR, et al. Preventing a first episode of psychosis: meta-analysis of randomized controlled prevention trials of 12 month and longer-term follow-ups. Schizophr Res. (2013) 149:56-62. doi: 10.1016/j.schres.2013.07.004
83. Stafford MR, Jackson H, Mayo-Wilson E, Morrison AP, Kendall T. Early interventions to prevent psychosis: systematic review and meta-analysis. BMJ (2013) 346:f185. doi: 10.1136/bmj.f185
84. Fusar-Poli P, Cappucciati M, Bonoldi I, Hui C, Rutigliano G, Stahl D, et al. Prognosis of brief psychotic episodes: a meta-analysis. JAMA Psychiatry (2016) 73:211-20. doi: 10.1001/jamapsychiatry.2015.2313
85. Fusar-Poli P, Cappucciati M, De Micheli A, Rutigliano G, Bonoldi I, Tognin S, et al. Diagnostic and prognostic significance of brief limited intermittent psychotic symptoms (BLIPS) in individuals at ultra high risk. Schizophr Bull. (2017) 43:48-56. doi: 10.1093/schbul/sbw151
86. Carrion RE, Correll CU, Auther AM, Cornblatt BA. A severity-based clinical staging model for the psychosis prodrome: longitudinal findings from the new york recognition and prevention program. Schizophr Bull. (2017) 43:64-74. doi: 10.1093/schbul/sbw155
87. Ahmed I, Debray TP, Moons KG, Riley RD. Developing and validating risk prediction models in an individual participant data meta-analysis. BMC Med Res Methodol. (2014) 14:3. doi: 10.1186/1471-2288-14-3
88. Keefe R, Woods S, Cannon T, Ruhrmann S, Mathalon D, McGuire P, et al. 868. Early intervention in attenuated psychosis syndrome: a phase II Study evaluating efficacy, safety, and tolerability of Oral BI 409306. Biological Psychiatry (2017) 81:S351. doi: 10.1016/j.biopsych.2017.02.593
89. Cannon TD, Yu C, Addington J, Bearden CE, Cadenhead KS, Cornblatt BA, et al. An individualized risk calculator for research in prodromal psychosis. Am J Psychiatry (2016) 173:980-8. doi: 10.1176/appi.ajp.2016.15070890
90. McGuire P, Englund A, Bhattacharyya S. Commentary on 'The Potential of Cannabidiol Treatment for Cannabis Users With Recent-Onset Psychosis.' Schizophr Bull. (2018) 44:18-9. doi: 10.1093/schbul/sbx124
91. Cannabidiol as a Novel Therapeutic Agent for Patients at Ultra High-Risk of Psychosis: An Experimental Medicine Approach. Available online at: http://gtr.rcuk.ac.uk/project/0C8EE617-3E76-48A8-A5BE-C726F0E0428A
92. Fusar-Poli P, Carpenter WT, Woods SW, McGlashan TH. Attenuated psychosis syndrome: ready for DSM-5.1? Ann Rev Clin Psychol. (2014) 10:155-92. doi: 10.1146/annurev-clinpsy-032813-153645
93. Altman DG, Bland JM. Statistics notes: absence of evidence is not evidence of absence. BMJ (1995) 311:485. doi: 10.1136/bmj.311.7003.485
94. Thorlund K, Mills EJ. Sample size and power considerations in network meta-analysis. Syst Rev. (2012) 1:41. doi: 10.1186/2046-4053-1-41